Uppsala, Sweden, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as new Chief Financial Officer (CFO). She will take up the position on September 1, succeeding Björn Petersson, who has been engaged on a consultancy basis. Cecilia Driving has extensive CFO experience, with particularly deep expertise in capital markets, investor relations, and business development gained from leading positions at companies in the clinical and commercial development phases.
Cecilia Driving most recently served as CFO at the defense and technology company W5 Solutions, where she, among other things, led the financing for an acquisition. Prior to that, she was CFO at Mabtech Holding, where she led a dual-track process that resulted in a sale to EQT. Cecilia has also held positions as Executive Vice President, CFO, and Head of HR and IR at Biovica International; CFO and Managing Director at RISE (Research Institutes of Sweden); and CFO and legal counsel roles at, among others, MedCap and Diamyd Medical. She has served on the boards of, among others, Ovzon and Embracer Group.
"We are very pleased to welcome Cecilia Driving to Dicot Pharma. Her solid experience in capital markets, investor relations and business development at life science companies makes her a perfect match for us at this stage of our development. At the same time, I would like to extend my sincere thanks to Björn Petersson, whose contributions have been highly valuable to the company during his more than four-year tenure as CFO," says Elin Trampe, CEO of Dicot Pharma.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.
